Monte Rosa Therapeutics, Inc. Revenue 2023–2025
Monte Rosa Therapeutics, Inc. annual/quarterly revenue history and growth rate from 2023 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Monte Rosa Therapeutics, Inc. revenue for the quarter ending March 31, 2026 was 4.2 M, a 95.04% decrease year-over-year.
- Monte Rosa Therapeutics, Inc. revenue for the twelve months ending March 31, 2026 was 125.1 M, a 735.40% increase year-over-year.
- Monte Rosa Therapeutics, Inc. annual revenue for 2025 was 123.7 M, a 63.54% increase from 2024.
- Monte Rosa Therapeutics, Inc. annual revenue for 2024 was 75.6 M.
- Monte Rosa Therapeutics, Inc. annual revenue for 2023 was 0.
Monte Rosa Therapeutics, Inc. (GLUE) — Frequently Asked Questions
Monte Rosa Therapeutics, Inc. (GLUE) is a publicly traded US company. It has a market capitalization of $1.37B. In fiscal 2025 it reported revenue of $124M and net income of -$39M. Explore GLUE's stock price, financial statements, earnings history, margins and key ratios below.
What is Monte Rosa Therapeutics, Inc.'s market cap?
Monte Rosa Therapeutics, Inc. (GLUE) has a market capitalization of $1.37B.
What is the GLUE stock price?
GLUE trades at $16.52 (-0.54% on the day).
How much revenue does Monte Rosa Therapeutics, Inc. make?
Monte Rosa Therapeutics, Inc. reported revenue of $124M in fiscal 2025.
Is GLUE profitable?
In fiscal 2025, Monte Rosa Therapeutics, Inc. reported net income of -$39M.